Skip to content
media1

Group News

Key ARV Products Viread® and Truvada® Registered by MCC

Apr 24, 2007

JSE listed Aspen, a leading global manufacturer and distributor of anti-retroviral (ARV) medicines, today announced that it has been granted certification from the Medicines Control Council of South Africa (MCC) to manufacture and distribute the two key ARV products Viread® (tenofovir disoproxil fumarate) and Truvada® (emtricitabine and tenofovir disoproxil fumarate) in the South African market.…

Read More >>

Tibotec and Aspen Collaborate on PREZISTA™ access plan for Africa

Apr 4, 2007

Co Cork, Ireland (April 4th, 2007) – Tibotec Pharmaceuticals Ltd. has signed a royalty-free, non-exclusive license agreement with Aspen of South Africa. Aspen will register, package and distribute the protease inhibitor PREZISTA™ (darunavir, DRV) in sub-Saharan Africa. Tibotec has selected Aspen because of the company’s extensive African distribution network and pioneering endeavors in enhancing access…

Read More >>

Aspen and Strides enter into broad and strategic partnership

Mar 7, 2007

Johannesburg South Africa, and Bangalore, India: Aspen Pharmacare (Aspen), Africa’s largest pharmaceutical manufacturer and the largest generics manufacturer in the southern hemisphere, has entered into a series of transactions with Bangalore-based Strides Arcolab Limited (Strides), one of India’s largest exporters of pharmaceutical products. The transactions comprise: the acquisition by Aspen of 50% of Strides’ Latin…

Read More >>

Aspen records 15% increase in revenue

Feb 26, 2007

Johannesburg – JSE listed Aspen (Apn), Africa’s largest pharmaceutical manufacturer, has recorded positive results for the period ended December 2006. Revenue increased by 15 percent to R1,936 billion (R1.687 billion). Net profit after tax rose 15 percent to R332 million (R288.5 million). Earnings per share increased by 13 percent to 95,3 cents (84,5 cents). Headline…

Read More >>

Appointment of Alternate Director

Feb 15, 2007

Aspen has appointed Derek Thomas, BCom (Finance and Economics); BCom (Hons) (Economics); MCOM (Economics); MSc (Economics), as an alternate director to Pasco Dyani with effect from 6 February 2007. Since 2000, Derek has served as CEO of CEPPWAWU Investments (Pty) Ltd, a broad based black economic empowerment investment company (wholly owned by a Trust formed…

Read More >>

Once-offs results in 235% increase in HEPS

Jan 8, 2007

Johannesburg – JSE listed Aspen (Apn), Africa’s largest pharmaceutical manufacturer, has announced impressive results for the financial year ended June 30, 2006. These are the first set of annual results reported under International Financial Reporting Standards (IFRS). Headline earnings per share (HEPS) grew by 235 percent to 185.5 cents (144.7 cents). Revenue increased by 23…

Read More >>

Aspen 3rd in FM 2006 Top Companies

Jun 15, 2006

Aspen was ranked third in the June 2006 Financial Mail Top Companies survey. Companies are ranked based on consistent performance for five years. Aspen wasn’t on the radar screen a few years ago; now it’s in third position and has a market capitalization in excess of R14 billion. Aspen’s share delivered a highly credible 112%…

Read More >>

Dr. Judy Dlamini appointed chairman designate at Aspen

Jun 11, 2006

Dr Judy Dlamini will succeed Archie Aaron as chairman of the board of directors of Aspen Pharmacare Holdings Limited (“Aspen”) after Aspen’s annual general meeting of shareholders which is scheduled to take place in November 2007. Archie Aaron has decided to step down as chairman having served in this position since 1999. He will remain…

Read More >>

Aspen to manufacture influenza medicine oseltamivir

May 16, 2006

Aspen (APN), South Africa’s largest listed pharmaceutical company, today announced that it has reached an agreement with Roche to produce a generic version of oseltamivir for Africa. This complements Roche’s continued efforts to increase and speed up availability of the medicine for world wide influenza pandemic planning. The agreement focuses on providing oseltamivir for pandemic…

Read More >>

Aspen signs MOU for TB products

Mar 2, 2006

Johannesburg – JSE listed Aspen (APN) and Indian based Lupin Limited have entered into a Memorandum of Understanding for the establishment of a 50:50 joint venture for the development, manufacture and global marketing of selected anti-tuberculosis (TB) products. The JV will also investigate opportunities to enter the Malaria market. Stephen Saad, Aspen Group Chief Executive…

Read More >>
Scroll To Top